Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas

NCT01660451 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01660451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01660451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Uncontrolled Phase II Trial of Intravenous PI3K Inhibitor BAY80-6946 in Patients With Relapsed, Indolent or Aggressive Non-Hodgkin's Lymphomas
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
November 19, 2012
Completion date
May 18, 2023
Enrollment
227 (actual)
Sites
102

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin